GRID EXPONENTIAL

Name

GRID EXPONENTIAL

Legal name

Grid Exponential

Website

https://gridexponential.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

GRID EXPONENTIAL (GRIDX) is a Latin American venture builder that co-founds biotech startups from deep science through its three-stage TRANSFORM program, deploying $41 MM in AUM across 90+ companies in 8 countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Buenos Aires

HQ country

Argentina

HQ region

Latin America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Venture Capital Returns: GRIDX generates returns through equity investments in early-stage biotech startups. They invest in scientific projects and startups in LATAM, taking equity stakes. Success metrics include follow-on capital raised by portfolio companies ($150+ MM raised from worldwide investors) and one-year-since-release companies re-invested by other funds worldwide (70%).

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Core offering

GRIDX operates a venture capital fund and startup builder that transforms cutting-edge scientific research from Latin America into globally competitive biotech startups. The core offering is the TRANSFORM Program — a structured three-stage process (Ignite for team matching and value proposition development; Build for business model validation; and Journey to Fundraising for investor preparation and international exposure) — delivered alongside staged equity investment across four investment domains: Agri-food/land use, Bio-industry, Human health, and Deep biotech.

Product overview

GRIDX (Grid Exponential) is a life-centered venture capital fund and startup accelerator that operates as a venture builder for the Latin American bioeconomy. The core offering is the TRANSFORM Program, a three-stage venture-building process (Ignite, Build, and Journey to Fundraising) that converts cutting-edge scientific research into globally impactful biotech startups. The company supports startups across four investment domains: Agri-food/land use, Bio-industry, Human health, and Deep biotech. GRIDX's services include scientific project discovery, interdisciplinary team matching, business development, mentorship, and investor readiness support, culminating in a portfolio of 90+ startups that have collectively raised over $150 million in follow-on capital.

Differentiator

Problem solved

Functional benefit

Products and services

• TRANSFORM Program A venture-building program that transforms cutting-edge science from LATAM researchers into high-impact biotech startups through a three-stage process: Ignite (3-month team matching and value proposition development), Build (3-month business model validation and market readiness), and Journey to Fundraising (6-month investor preparation and international roadshow exposure). Delivered alongside staged equity investment (20% at Ignite, 60% at Build).
• GRIDX Startup Portfolio A portfolio of 90+ biotech startups across Latin America spanning agriculture, bio-industry, healthcare, and deep biotechnology sectors. Portfolio companies have collectively raised over $150 million in follow-on capital, with 70% of one-year-since-release companies re-invested by other funds worldwide. Examples include Stämm (continuous biomanufacturing), Puna Bio (extremophile bioinoculants), CASPR (CRISPR diagnostics), Beeflow (professional pollination), Michroma (fungal food ingredients), OncoPrecision (patient-derived cancer antibodies), Bioeutectics (bio-based solvents), and Nanogrow (nanobody therapeutics).
• Investment Thesis (Life-Centered Fund) A life-centered investment strategy focused on the bioeconomy transition, deploying capital into startups across four domains: Agri-food/land use (soil/crop handling, sustainable agriculture, biological inputs, food technologies), Bio-industry (biomaterials, bioprocesses, green solvents replacing petrochemical products), Human health (diagnostics, therapeutics, medical devices, fertility treatments), and Deep biotech (bioinformatics, biodigital tech stack, enabling technologies).

Quantifiable outcome

• 90+ startups founded since 2015
• +4 more outcomes

Segments6 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core and minor.

• Strategic Advisors and MentorscoreOthersGRIDX connects portfolio companies with strategic advisors and mentors throughout the Journey to Fundraising stage. Mentorship is provided through targeted 1-on-1 sessions for business growth and collaborative update meetings.
• NY/SF Roadshow NetworkminorGTM or Marketing PartnerGRIDX facilitates roadshows to New York and San Francisco for portfolio companies to connect with international investors and partners. This provides global exposure and access to major innovation hub ecosystems.
• Tulsa ConnectionminorGTM or Marketing PartnerPartnership providing portfolio companies with connections to the Tulsa innovation ecosystem as part of international exposure activities.

Scale indicators17 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• IndieBio (SOSV): Global biotech venture builder and accelerator program of SOSV. IndieBio is a direct comparator because it also runs a multi-stage program that selects deep-science founders, builds interdisciplinary teams, and provides staged capital plus lab infrastructure — the same venture-building model GRIDX runs for LATAM biotech.
• Petri: US-based biotech startup accelerator backing early-stage founders across human health, agriculture and industrial biology. Petri overlaps with GRIDX on the early-stage biotech accelerator model and the breadth of life-science domains supported.
• BioGenerator: St. Louis-based biotech venture builder and investor that creates and funds early-stage life-science companies. Comparable to GRIDX as a regionally anchored biotech venture builder with a structured company-creation engine.
• Creative Destruction Lab: Science- and technology-focused accelerator with a structured mentorship-driven program for science-based ventures. Comparable to GRIDX in providing a staged, objective-based program for founders commercializing deep-tech research.
• Antler: Global venture builder that recruits and backs founders from inception through company creation. Comparable to GRIDX in the venture-building philosophy of team-formation and staged capital, though Antler invests across sectors beyond biotech.

Emerging players

• MBC BioLabs: Biotech incubator offering lab space and operational support to early-stage life-science startups, with a venture-building ethos. Comparable to GRIDX in supporting pre-seed and seed biotech founders, though it focuses on providing infrastructure rather than staged equity capital.

Broad incumbents

• Flagship Pioneering: Large, established biotech venture-creation firm originating companies like Moderna. Comparable to GRIDX in the company-creation philosophy but operates at much larger scale and across global therapeutics rather than regionally diversified LATAM biotech.

Others

• Andreessen Horowitz Bio / a16z Bio: Major US venture firm with a dedicated bio fund investing across biotech and digital health. Comparable to GRIDX as a deep-tech biotech investor but at materially larger fund scale and with broader global reach.
• SVB / Silicon Valley Bank Venture Capital Relationships: Banking and venture-finance partner historically embedded in the US venture ecosystem. Comparable as an enabling financial institution serving VC-backed biotech, though it is not a direct venture builder like GRIDX.

Regional players

• Kaszek Ventures: Leading LATAM-focused venture capital firm investing across technology sectors in the region. Comparable to GRIDX as a major LATAM venture investor and brand, though Kaszek focuses on broader tech verticals rather than biotech specialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCP0IJ-At85_NmaceOJfuBmA
• Xx.com/gridexp

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments96 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GRID EXPONENTIAL